Benefits of danazol treatment in patients with hemophilia A (classic hemophilia).
Danazol, an attenuated androgen, was given intermittently in three patients with hemophilia A. The rise in factor VIII activity with danazol treatment was associated with a fivefold decrease in hemorrhagic episodes and plasma concentrate product utilization when compared with similar periods without the drug. Four other patients with moderate hemophilia A who received danazol for 14 days had an increase of 400% to 850% in their factor VIII levels. Of four patients without detectable levels of factor VIII who were treated with danazol, two had elevations of the factor VIII level, to 3% and 4%, respectively. Danazol appears to be an effective treatment for patients with hemophilia A.
D000328:Adult; D001803:Blood Transfusion; D003613:Danazol / Q000627:therapeutic use*; D005169:Factor VIII / Q000378:metabolism*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011245:Pregnadienes / Q000627:therapeutic use*; D013997:Time Factors
D011245:Pregnadienes; D005169:Factor VIII; D003613:Danazol